Lala Ceklic1,2, Wolfgang Huf3, Andreas Ebneter1, Sebastian Wolf1,2, Martin S Zinkernagel1,2, Marion R Munk1,2,4. 1. Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 2. Bern Photographic Reading Center, University Hospital Bern, Bern, Switzerland. 3. Karl Landsteiner Institute for Clinical Risk Management, Vienna, Austria. 4. Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Abstract
PURPOSE: To investigate the prevalence and impact of ganglion cell layer cysts (GCLC) in patients with diabetic macular oedema (DME) under continuous anti-vascular endothelial growth factor (VEGF) therapy. METHODS: The clinical findings and spectral domain optical coherence devices of baseline visits and follow-up after 12-24 and 36 months of DME patients under continuous anti-VEGF therapy were retrospectively collected and analysed for the impact of GCLC cysts. Previously established prognostic parameters were also assessed. RESULTS: A total of 110 eyes of 110 DME patients (mean age 64 ± 10 years) were included. At baseline, 17% eyes had GCLC. With GCLC, the best-corrected visual acuity (BCVA) improvement was in mean 8.4 ± 2.4 Early-Treatment-Diabetic-Retinopathy-Study (ETDRS) letters less over the course of 36 months compared to the group lacking GCLC (p = 0.0009). Eyes with GCLC showed 68 ± 23.4 μm less central retinal thickness (CRT) decrease than eyes lacking GCLC (p < 0.0001). In the linear mixed effect models including external limiting membrane disruption, disintegration of inner retinal layer and epiretinal membrane, GCLC remained a statistical significant factor for the outcome parameter CRT, but missed statistical significance for BCVA. CONCLUSION: Ganglion cell layer cysts (GCLC) seem to impact outcome in DME in patients receiving long-term treatment. This prognostic factor warrants further evaluation in the context of already well-established outcome parameters.
PURPOSE: To investigate the prevalence and impact of ganglion cell layer cysts (GCLC) in patients with diabetic macular oedema (DME) under continuous anti-vascular endothelial growth factor (VEGF) therapy. METHODS: The clinical findings and spectral domain optical coherence devices of baseline visits and follow-up after 12-24 and 36 months of DMEpatients under continuous anti-VEGF therapy were retrospectively collected and analysed for the impact of GCLC cysts. Previously established prognostic parameters were also assessed. RESULTS: A total of 110 eyes of 110 DMEpatients (mean age 64 ± 10 years) were included. At baseline, 17% eyes had GCLC. With GCLC, the best-corrected visual acuity (BCVA) improvement was in mean 8.4 ± 2.4 Early-Treatment-Diabetic-Retinopathy-Study (ETDRS) letters less over the course of 36 months compared to the group lacking GCLC (p = 0.0009). Eyes with GCLC showed 68 ± 23.4 μm less central retinal thickness (CRT) decrease than eyes lacking GCLC (p < 0.0001). In the linear mixed effect models including external limiting membrane disruption, disintegration of inner retinal layer and epiretinal membrane, GCLC remained a statistical significant factor for the outcome parameter CRT, but missed statistical significance for BCVA. CONCLUSION: Ganglion cell layer cysts (GCLC) seem to impact outcome in DME in patients receiving long-term treatment. This prognostic factor warrants further evaluation in the context of already well-established outcome parameters.
Authors: Bhim B Rai; Ted Maddess; Corinne F Carle; Emilie M F Rohan; Josh P van Kleef; Richard C Barry; Rohan W Essex; Christopher J Nolan; Faran Sabeti Journal: Transl Vis Sci Technol Date: 2021-11-01 Impact factor: 3.283
Authors: Marion R Munk; Gabor Mark Somfai; Marc D de Smet; Guy Donati; Marcel N Menke; Justus G Garweg; Lala Ceklic Journal: Int J Mol Sci Date: 2022-07-08 Impact factor: 6.208